SCHEMBL3263464

SCHEMBL3263464

C=CCc1cc2ccccc2nc1NCCCCC

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 7/20 0.48
NPSR1 Q6W5P4 2/20 0.47
KDM4E B2RXH2 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
S1PR2 O95136 1/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CHEK2 O96017 1/20 0.42
FLT1 P17948 1/20 0.42
CASP6 P55212 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
TRIM58 Q8NG06 1/20 0.41
TOP2A P11388 4/20 0.41
ACP1 P24666 1/20 0.40
GBA1 P04062 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3263288 0.75 ACP1 (0.52) TLR8NPSR1KDM4EL3MBTL1S1PR2
SCHEMBL28426308 0.74 TLR8 (0.73) TLR8NPSR1KDM4EL3MBTL1S1PR2
SCHEMBL11565010 0.72 ADRA2B (0.45) TLR8NPSR1L3MBTL1S1PR2LMNA
SCHEMBL9669792 0.71 CNR1 (0.41) NPSR1KDM4ES1PR2LMNASMN1; SMN2
SCHEMBL8213737 0.70 TLR8 (0.49) TLR8KDM4EMEN1ALDH1A1MAPT
SCHEMBL8672800 0.70 TLR8 (0.49) TLR8KDM4ESMN1; SMN2MEN1ALDH1A1
SCHEMBL8636728 0.69 CCNB2 (0.36) TLR8NPSR1S1PR2LMNASMN1; SMN2
SCHEMBL28962059 0.68 TLR8 (0.53) TLR8NPSR1KDM4EL3MBTL1S1PR2
SCHEMBL9242375 0.68 TLR8 (0.48) TLR8NPSR1KDM4ELMNASMN1; SMN2
SCHEMBL2818584 0.68 TLR8 (0.68) TLR8KDM4EALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221371-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-08-07 US disclosed
US-20100041698-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221371-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, HTR1A, HTR2C TLR8 3013/4885NPSR1 44/4885KDM4E 3028/4885
US-20100041698-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, HTR1A, HTR2C TLR8 3013/4885NPSR1 44/4885KDM4E 3028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.